Table 2 Characteristics of the participants in the included studies
Study ID | Groups | Number | Male (%) | Age (median) | Smoking Status | Histopathology | ECOG performance status | Tumor stage | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Former | Current | Never | SCC | ADC | ASC | Other | 0 | 1 | Locally advanced (IIIB) | Metastatic (IV) | |||||
Li et al. 2022 [18] | TS + CT CT | 33 33 | 15 (45.4) 14 (42.4) | 65.74 (59–78) 65.58 (58–78) | N/A N/A | N/A N/A | N/A N/A | 0 0 | 33 (100) 33 (100) | 0 0 | 0 0 | N/A N/A | N/A N/A | N/A N/A | N/A N/A |
Lu et al. 2021 [19] | TS + CT CT | 223 111 | 168 (75.3) 79 (71.2) | 60 (27–75) 61 (25–74) | 115 (51.6) 53 (47.7) | 32 (14.3) 13 (11.7) | 76 (34.1) 45 (40.5) | N/A N/A | 215 (96.4) 107 (96.4) | 1 (0.4) 2 (1.8) | 7 (3.1) 2 (1.8) | 54 (24.2) 24 (21.6) | 169 (75.8) 87 (78.4) | 40 (17.9) 21 (18.9) | 183 (82.1) 90 (81.1) |
Wang et al. 2021 [20] | Arm A: TS + CT (PTX + CBP) Arm B: TS + CT (nab PTX + CBP) Arm C: CT (PTX + CBP) | 120 119 121 | 107 (89.2) 112 (94.1) 111 (91.7) | 60 (41–74) 63 (38–74) 62 (34–74) | 96 (80.0) 107 (89.9) 98 (81.0) | 24 (20.0) 12 (10.1) 23 (19.0) | TS + CT: 239 (100) CT: 121 (100) | N/A N/A | N/A N/A | N/A N/A | 31 (25.8) 22 (18.5) 32 (26.4) | 89 (74.2) 97 (81.5) 89 (73.6) | 38 (31.7) 40 (33.6) 44 (36.4) | 82 (68.3) 79 (66.4) 77 (63.6) | |
Zhou et al. 2022 [21] | TS CT | 535 270 | 416 (77.8) 206 (76.3) | 61.0 (28–88) 61.0 (32–81) | 373 (69.7) 188 (69.6) | 162 (30.3) 82 (30.4) | 248 (46.4) 122 (45.2) | N/A N/A | N/A N/A | N/A N/A | 116 (21.7) 50 (18.5) | 419 (78.3) 220 (81.5) | 84 (15.7) 33 (12.2) | 451 (84.3) 237 (87.8) | |